Delic Labs President and CSO Dr. Markus Roggen Named to Cannabis Scientist Power List for Third Consecutive Year
Delic Holdings Corp celebrates Dr. Markus Roggen, President and Chief Science Officer of Delic Labs, named to the Cannabis Scientist Power List for the third consecutive year. This recognition highlights his impactful work in cannabis research. Under his leadership, Delic Labs has received 56 exemptions from Health Canada for chemistry analytics on psilocybin mushrooms and is set to acquire a Dealer's License to commercialize psilocybin research. Delic aims to enhance quality control standards in psychedelic medicine.
- Dr. Markus Roggen recognized on the Cannabis Scientist Power List for third consecutive year, showcasing industry influence.
- Delic Labs received 56 exemptions from Health Canada for psilocybin research, enhancing credibility.
- Anticipation of obtaining a Dealer's License to commercialize psilocybin research, positioning Delic as a market leader.
- None.
The Cannabis Scientist Power List is an annual recognition of the most important innovators within the cannabis industry
VANCOUVER, BC, July 20, 2022 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today celebrated Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, being named to the Cannabis Scientist Power List for the third consecutive year. Dr. Markus Roggen is consistently recognized as one of the most influential figures in the processing professionals category because of his commitment to creating a body of work on cannabis research that will have a lasting effect on the industry for the better.
Under Dr. Roggen's leadership, Delic Labs will transfer their expertise and experience from the cannabis sector to establish itself as the leader in psychedelic research and safety testing. The lab has received Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms; to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD; and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs expects to receive within the next months a Dealer's License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.
With the Health Canada 56 exemptions and a Dealer's License, the Company plans to implement consistent quality control standards to enhance the use of psychedelic compounds for medical purposes.
To learn more about Dr. Markus Roggen's inclusion on the Cannabis Scientist Power List, please visit https://thecannabisscientist.com/power-list/2022.
Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The Company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.
In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/delic-labs-president-and-cso-dr-markus-roggen-named-to-cannabis-scientist-power-list-for-third-consecutive-year-301589832.html
SOURCE Delic Holdings Inc.
FAQ
Who is Dr. Markus Roggen and why is he important to Delic Holdings Corp?
What is the significance of the 56 exemptions received by Delic Labs from Health Canada?
What does it mean for Delic Labs to receive a Dealer's License?
How does Dr. Roggen's recognition impact Delic Holdings Corp's stock (DELCF, DELCF)?
